這是一項 Ib/II 期開放標籤研究。劑量遞增部分將表徵 JDQ443 單藥及 JDQ443 與其他研究治療（TNO155 和 tislelizumab）聯合在晚期實體瘤患者中的安全性和耐受性。
適應症：KRAS G12C Mutant Solid Tumors、Carcinoma, Non-Small-Cell Lung、Carcinoma, Colorectal、Cancer of Lung、Cancer of the Lung、Lung Cancer、Neoplasms, Lung、Neoplasms, Pulmonary、Pulmonary Cancer、Pulmonary Neoplasms
收案條件
納入條件
- Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies
- ECOG Performance Status of 0 or 1
- At least one measurable lesion as defined by RECIST 1.1
- Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion
排除條件
- Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations
- Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible
- Clinically significant cardiac disease or risk factors at screening
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。